Conserved Targets to Prevent Emerging Coronaviruses

Novel coronaviruses emerged as zoonotic outbreaks in humans in 2003 (SARS), 2012 (MERS), and notably in 2019 (SARS2), which resulted in the COVID-19 pandemic, causing worldwide health and economic disaster. Vaccines provide the best protection against disease but cannot be developed and engineered q...

Full description

Bibliographic Details
Main Authors: Fernanda Gonzalez Lomeli, Nicole Elmaraghy, Anthony Castro, Claudia V. Osuna Guerrero, Laura L. Newcomb
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/14/3/563
_version_ 1797440980599701504
author Fernanda Gonzalez Lomeli
Nicole Elmaraghy
Anthony Castro
Claudia V. Osuna Guerrero
Laura L. Newcomb
author_facet Fernanda Gonzalez Lomeli
Nicole Elmaraghy
Anthony Castro
Claudia V. Osuna Guerrero
Laura L. Newcomb
author_sort Fernanda Gonzalez Lomeli
collection DOAJ
description Novel coronaviruses emerged as zoonotic outbreaks in humans in 2003 (SARS), 2012 (MERS), and notably in 2019 (SARS2), which resulted in the COVID-19 pandemic, causing worldwide health and economic disaster. Vaccines provide the best protection against disease but cannot be developed and engineered quickly enough to prevent emerging viruses, zoonotic outbreaks, and pandemics. Antivirals are the best first line of therapeutic defense against novel emerging viruses. Coronaviruses are plus sense, single stranded, RNA genome viruses that undergo frequent genetic mutation and recombination, allowing for the emergence of novel coronavirus strains and variants. The molecular life cycle of the coronavirus family offers many conserved activities to be exploited as targets for antivirals. Here, we review the molecular life cycle of coronaviruses and consider antiviral therapies, approved and under development, that target the conserved activities of coronaviruses. To identify additional targets to inhibit emerging coronaviruses, we carried out in silico sequence and structure analysis of coronavirus proteins isolated from bat and human hosts. We highlight conserved and accessible viral protein domains and residues as possible targets for the development of viral inhibitors. Devising multiple antiviral therapies that target conserved viral features to be used in combination is the best first line of therapeutic defense to prevent emerging viruses from developing into outbreaks and pandemics.
first_indexed 2024-03-09T12:16:17Z
format Article
id doaj.art-db2ff8b4876e403d85ca96b2040ca566
institution Directory Open Access Journal
issn 1999-4915
language English
last_indexed 2024-03-09T12:16:17Z
publishDate 2022-03-01
publisher MDPI AG
record_format Article
series Viruses
spelling doaj.art-db2ff8b4876e403d85ca96b2040ca5662023-11-30T22:46:20ZengMDPI AGViruses1999-49152022-03-0114356310.3390/v14030563Conserved Targets to Prevent Emerging CoronavirusesFernanda Gonzalez Lomeli0Nicole Elmaraghy1Anthony Castro2Claudia V. Osuna Guerrero3Laura L. Newcomb4Biology Department, California State University, San Bernardino, CA 92407, USABiology Department, California State University, San Bernardino, CA 92407, USABiology Department, California State University, San Bernardino, CA 92407, USABiology Department, California State University, San Bernardino, CA 92407, USABiology Department, California State University, San Bernardino, CA 92407, USANovel coronaviruses emerged as zoonotic outbreaks in humans in 2003 (SARS), 2012 (MERS), and notably in 2019 (SARS2), which resulted in the COVID-19 pandemic, causing worldwide health and economic disaster. Vaccines provide the best protection against disease but cannot be developed and engineered quickly enough to prevent emerging viruses, zoonotic outbreaks, and pandemics. Antivirals are the best first line of therapeutic defense against novel emerging viruses. Coronaviruses are plus sense, single stranded, RNA genome viruses that undergo frequent genetic mutation and recombination, allowing for the emergence of novel coronavirus strains and variants. The molecular life cycle of the coronavirus family offers many conserved activities to be exploited as targets for antivirals. Here, we review the molecular life cycle of coronaviruses and consider antiviral therapies, approved and under development, that target the conserved activities of coronaviruses. To identify additional targets to inhibit emerging coronaviruses, we carried out in silico sequence and structure analysis of coronavirus proteins isolated from bat and human hosts. We highlight conserved and accessible viral protein domains and residues as possible targets for the development of viral inhibitors. Devising multiple antiviral therapies that target conserved viral features to be used in combination is the best first line of therapeutic defense to prevent emerging viruses from developing into outbreaks and pandemics.https://www.mdpi.com/1999-4915/14/3/563COVID-19coronaviruszoonosisantiviral
spellingShingle Fernanda Gonzalez Lomeli
Nicole Elmaraghy
Anthony Castro
Claudia V. Osuna Guerrero
Laura L. Newcomb
Conserved Targets to Prevent Emerging Coronaviruses
Viruses
COVID-19
coronavirus
zoonosis
antiviral
title Conserved Targets to Prevent Emerging Coronaviruses
title_full Conserved Targets to Prevent Emerging Coronaviruses
title_fullStr Conserved Targets to Prevent Emerging Coronaviruses
title_full_unstemmed Conserved Targets to Prevent Emerging Coronaviruses
title_short Conserved Targets to Prevent Emerging Coronaviruses
title_sort conserved targets to prevent emerging coronaviruses
topic COVID-19
coronavirus
zoonosis
antiviral
url https://www.mdpi.com/1999-4915/14/3/563
work_keys_str_mv AT fernandagonzalezlomeli conservedtargetstopreventemergingcoronaviruses
AT nicoleelmaraghy conservedtargetstopreventemergingcoronaviruses
AT anthonycastro conservedtargetstopreventemergingcoronaviruses
AT claudiavosunaguerrero conservedtargetstopreventemergingcoronaviruses
AT lauralnewcomb conservedtargetstopreventemergingcoronaviruses